Your browser doesn't support javascript.
loading
Next generation Fc scaffold for multispecific antibodies.
Estes, Bram; Sudom, Athena; Gong, Danyang; Whittington, Douglas A; Li, Vivian; Mohr, Christopher; Li, Danqing; Riley, Timothy P; Shi, Stone D-H; Zhang, Jun; Garces, Fernando; Wang, Zhulun.
Afiliación
  • Estes B; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Sudom A; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., San Francisco, CA 94080, USA.
  • Gong D; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Whittington DA; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Cambridge, MA 02141, USA.
  • Li V; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Mohr C; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Li D; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Riley TP; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Shi SD; Department of Process Development, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Zhang J; Department of Process Development, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Garces F; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., Thousand Oaks, CA 91320, USA.
  • Wang Z; Department of Therapeutics Discovery, Amgen Research, Amgen Inc., San Francisco, CA 94080, USA.
iScience ; 24(12): 103447, 2021 Dec 17.
Article en En | MEDLINE | ID: mdl-34877503
ABSTRACT
Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3' interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: IScience Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: IScience Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos